Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135679 · ClinicalTrials.gov registry record
The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 204
- Enrollment target
NCT02135679: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02135679 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 204 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02135679 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 204 participants
- Enrollment target
Study Summary
CTC levels collected pre-surgery will be correlated with pathological samples.
Primary Outcome
The pattern of CTCs before and after definitive radiotherapy for each treatment stratum. CTC counts per mL before and after definitive radiotherapy.
Interventions
- RADIATION Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2012-09 |
| Est. Completion | 2021-12 |
What the finished NCT02135679 record still lists
NCT02135679 is an observational study that tracks outcomes without assigning an intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Radiotherapy is the first listed.
NCT02135679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02135679 about?
NCT02135679 is a clinical study titled "The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy". CTC levels collected pre-surgery will be correlated with pathological samples.
What is the current status of trial NCT02135679?
This trial is currently completed. The enrollment target is 204 participants. The study started on 2012-09. Estimated completion is 2021-12.
What interventions are being tested in trial NCT02135679?
The interventions under investigation include: Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02135679?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia